All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Ten years after the outbreaks of Severe Acute Respiratory Syndrome (SARS) occurred in 29 countries, another novel coronavirus named Middle East Respiratory Syndrome coronavirus (MERS-CoV) was first found in the Middle East, in 2012 \[[@pone.0149988.ref001], [@pone.0149988.ref002]\]. The novel coronaviruses responsible for both SARS and MERS infections are zoonotic viruses. Civet cats and bats were identified as the sources of SARS-CoV infections in humans, whereas camels and bats were associated with human MERS-CoV infections \[[@pone.0149988.ref003]--[@pone.0149988.ref005]\]. Both viruses spread to an intermediate mammalian host from which humans are infected. Although human-to-human transmission occurred, this was mainly within households and medical care facilities, where healthcare personnel (HCP) were affected the most. However, super spreading events were reported in the SARS and MERS outbreak \[[@pone.0149988.ref006], [@pone.0149988.ref007]\].

Previous studies also indicated that HCP were a major high-risk population for infections with SARS-CoV and MERS-CoV \[[@pone.0149988.ref008], [@pone.0149988.ref009]\], but the information was very fragmented. Here, based on a series of HCP laboratory-confirmed MERS and SARS infections obtained from the World Health Organization and Taiwan, respectively, we compared the epidemiological and clinical characteristics, and particular similarities as well as differences between the two coronavirus infections to measure the risks related to fatal outcomes in both HCP and total cases. These data will be of benefit for effective prevention and control for any future nosocomial outbreaks of novel Coronavirus, and will therefore promote occupational health.

Materials and Methods {#sec002}
=====================

Sources of study populations {#sec003}
----------------------------

All the laboratory-confirmed MERS cases were obtained from various publicly available sources from April 1 of 2012 to July 7 of 2015, including the published literature and data reported to the World Health Organization (<http://www.who.int/csr/don/archive/disease/coronavirus_infections/en/>) (**[S1 Table](#pone.0149988.s001){ref-type="supplementary-material"})**. All laboratory-confirmed SARS cases were reported to the WHO from Taiwan during November 1 of 2002 to December 31, 2003 (<http://www.who.int/csr/sars/country/table2004_04_21/en/>), after the final decision by the SARS Advisory Committee members in Taiwan (**[S2 Table](#pone.0149988.s002){ref-type="supplementary-material"})**.

Case definitions {#sec004}
----------------

According to the WHO guideline, a laboratory-confirmed case with MERS-CoV was defined as as either detection of viral nucleic acid or confirmation by serology \[[@pone.0149988.ref010]\].Based on the WHO guideline, the case definitions for SARS cases were confirmed by several different laboratory tests, including confirmation of the RT-PCR results from two different laboratories or two different specimens collected from the same person, and/or serological tests by ELISA.

Epidemiologic investigations and laboratory tests {#sec005}
-------------------------------------------------

Once cases were suspected to be clinical SARS cases, preliminary investigation was conducted using a standardized questionnaire about demographic characteristics and exposure history, clinical features, and laboratory results. Respiratory samples obtained from any reported suspected SARS cases were sent to the Center for Disease Control in Taiwan (Taiwan-CDC) for confirmation by RT-PCR or serology. The details of all the laboratory methods (molecular RT-PCR or serological tests) to confirm SARS-CoV were as previously described \[[@pone.0149988.ref011]\].

Statistical analysis {#sec006}
--------------------

Regional incidence rates are shown on the map using the bio-geographical information system software ArcGIS Map10.2 (<http://resources.arcgis.com/en/home/>). We used the ggplot function from the R package "ggplot2" to draw the boxplots of age distribution between MERS and SARS cases.

Quantitative measurements are presented as the mean and range of the observed values, and qualitative measurements are presented as relative and absolute frequencies. Categorical and continuous characteristics were analyzed with a chi-squared test and t test, respectively. All statistical analyses were conducted using SAS 9.2 (SAS Institute, Cary, NC, USA). Any *p* values given are two-sided and subject to a local significance level of 0.05.

Results {#sec007}
=======

Epidemiological comparison {#sec008}
--------------------------

### Geographical distribution {#sec009}

As of 7 July 2015, 1368 laboratory-confirmed human MERS-CoV cases had been reported to the WHO, 487 of whom died (35.6%). All of these MERS cases were distributed in 26 countries, particularly predominant in the Arabian Peninsula and South Korea. However, global MERS-HCP cases occurred in 6 countries; see [Table 1](#pone.0149988.t001){ref-type="table"} **and [Fig 1](#pone.0149988.g001){ref-type="fig"}.** MER-HCP accounted for 13.37% (183/1368) of overall MERS cases in the world.

![Geographical distribution of 1368 laboratory-confirmed cases, 487 deaths and 183 healthcare personnel (HCP) infected with MERS-CoV from April 1 of 2012 to July 7 of 2015.\
Notes: 1a: Overall MERS cases and the case fatality rate. The denominator is the cumulative number of total cases with MERS-CoV; Numerator is the case fatality rate in total cases. 1b: Overall MERS cases and percent of HCP with MERS infections. The denominator is the cumulative number of total cases with MERS-CoV; Pie represents the percentage of HCP and non HCP among the total cases.](pone.0149988.g001){#pone.0149988.g001}

10.1371/journal.pone.0149988.t001

###### Epidemiologic comparison of the laboratory-confirmed human infections with MERS-CoV and SARS-CoV\* in healthcare personnel (HCP) and total cases as of July 7, 2015.

![](pone.0149988.t001){#pone.0149988.t001g}

  Epidemiologic Characteristics   MERS-CoV (+)       SARS-CoV (+)            Comparisons                                                                
  ------------------------------- ------------------ ----------------------- ------------- ------------------ ----------------------- ------- --------- ---------
  **Outbreak Area**                                                                                                                                     
      No. of countries/areas      6                  26                      NA            9                  29                      NA      NA        NA
      Most affected Countries     Saudi Arabia       Saudi Arabia            NA            China              China                   NA      NA        NA
  **Epidemic Curve**                                                                                                                                    
      Starting month              April of 2012      April of 2012           NA            January of 2003    November of 2002        NA      NA        NA
      Peaking month               Spring             Spring and summer       NA            NA                 Spring and winter       NA      NA        NA
      Months of epidemic period   \>39               \>39                    NA            8                  8                       NA      NA        NA
  **Clusters**                                                                                                                                          
      Super-spreader              Yes                Yes                     NA            Yes                Yes                     NA      NA        NA
      Cluster size                NA                 2.3 (1\~26)             NA            NA                 8 (0\~125)              NA      NA        NA
      Outbreak areas              Hospitals (Hosp)   Hosp, Households (HH)   NA            Hospitals          Hosp, HH, Communities   NA      NA        NA
  **Animal Sources**              No                 Bat and camel           No            NA                 Civet cat and bat       NA      NA        NA
  **Human Cases**                                                                                                                                       
      Percent of HCP cases        NA                 13.37% (183/1368)       NA            NA                 21.07% (1706/8096)      NA      0.000     NA
      Mean age (yr)               40 (24\~74)        49 (2\~90)              0.035         35 (21\~68)\*      42 (0\~94)              0.044   0.006     0.0002
      Male/total%                 54.46% (55/101)    65% (883/1359)          0.002         17.35% (17/98)\*   46.93% (3778/8050)      0.027   \<0.001   \<0.001
      Overall CFR                 NA                 35.6% (487/1368)        NA            NA                 9.6% (774/8096)         NA      NA        \<0.001
  **Working place for HCP**                                                                                                                             
      Emergency rooms             17.65% (3/17)      NA                      NA            31.58%（18/57)     NA                      NA      0.943     NA
      Intensive care units        58.82% (10/17)     NA                      NA            10.53%（6/57)      NA                      NA      \<0.001   NA
      Internal medicine wards     11.76% (2/17)      NA                      NA            26.31% (15/57）    NA                      NA      0.704     NA
      Others                      11.76% (2/17)      NA                      NA            31.58%（18/57)     NA                      NA      0.507     NA
      Unknown                     166                NA                      NA            41                 NA                      NA      NA        NA

**Denotations: *p***~***1***~: comparison of HCP and non-HCP cases infected with MERS-CoV; ***p***~**2:**~ comparison of HCP and non-HCP cases infected with SARS-CoV; ***p***~***3*:**~ comparison of HCP infected with MERS-CoV and SARS-CoV; ***p***~***4***~**:** comparison of total MERS-CoV and total SARS-CoV cases. CFR: Case Fatality Rate; NA: No available data

\*SARS-CoV Data were obtained from Taiwan.

By contrast, as of 31 December 2003, 8096 laboratory-confirmed global human SARS-CoV cases had been reported to the WHO, 774 of whom died (9.6%). These SARS cases were distributed in 29 countries, particularly predominant in Asian areas. The percent of the SARS-HCP in total cases was higher than the percent of the MERS-HCP \[21.07% (1706/8096) vs 13.37% (183/1368), *p*\<0.001\]. The CFR in overall MERS was statistically significantly higher than that of overall SARS \[35.6% (487/1368) vs 9.6% (774/8096), *p*\<0.001\]. (**[Table 1](#pone.0149988.t001){ref-type="table"} and [Fig 2](#pone.0149988.g002){ref-type="fig"}).**

![Geographical distribution of 8096 laboratory-confirmed cases, 774 deaths and 1706 HCP infected with SARS-CoV from November 1 of 2002 to December 31, 2003.\
Notes: 1a: Overall SARS cases and the case fatality rate. The denominator is the cumulative number of total cases with SARS-CoV; Numerator is the case fatality rate in total cases. 1b: Overall SARS cases and percent of HCP with SARS infections. The denominator is the cumulative number of total cases with SARS-CoV; Pie represents the percentage of HCP and non HCP among the total cases.](pone.0149988.g002){#pone.0149988.g002}

### Demographical and occupational exposure {#sec010}

The mean age in worldwide total 174 MERS cases was 49 years (range: 2\~90 years), of which 143 MERS-HCP cases were aged 40 years (range: 24\~74 years), significantly younger than in 31 MERS-non-HCP cases \[47.5 years (range: 2\~90 years), *p* = 0.035\]. Similarly, the mean age in 347 total Taiwan SARS cases was 42 years (range: 0\~94), of which the mean age in 98 SARS-HCP cases was 35 years (range: 21\~68 years), also much younger than that of SARS-non-HCP \[45 years (range: 0\~94 years), *p =* 0.044\]. Noticeably, the mean ages of MERS-HCP and total MERS cases were significantly older than those for SARS-HCP (*p =* 0.006) and total SARS cases in Taiwan (*p =* 0.0002). (**[Fig 3A and 3B](#pone.0149988.g003){ref-type="fig"} and [Table 1](#pone.0149988.t001){ref-type="table"}).** We stratified the age groups between the MERS-HCP and SARS-HCP cases; the results show that there are no signature differences in the mean age of the 20\~, 30\~, 40\~, 50\~, 60--70 groups between the two groups.

![The age distribution in the laboratory-confirmed cases with MERS and SARS from Taiwan in overall population and HCP.\
Note: 3a: MERS (N = 174) and SARS (N = 347) infections in overall cases. 3b: MERS-HCP (N = 143) and SARS-HCP (N = 98) cases.](pone.0149988.g003){#pone.0149988.g003}

In terms of sex distribution, among MERS cases whose gender information was available, 65% of 1359 total MERS cases were male, of which 54.46% of 101 MERS-HCP and 69.55% of 1258 MERS-non-HCP \[*p =* 0.002\] were male respectively. However, in Taiwan females were dominant in the 98 SARS-HCP cases (82.65%, 81/98) and 249 SARS-non-HCP cases (55.0%, 137/249) \[p = 0.027\], while males accounted for 46.93% (3778/8050) of total global SARS cases. **([Fig 3A and 3B](#pone.0149988.g003){ref-type="fig"} and [Table 1](#pone.0149988.t001){ref-type="table"}).** We stratified the gender groups between the MERS-HCP and SARS-HCP cases, with the results showing significant differences in the gender distribution of the 20\~, 30\~, 40\~, 50\~, 60--70 groups between the two groups.

Regarding the working departments of HCP, 58.82% (10/17) of MERS-HCP cases worked in an intensive care unit (ICU), while 17.65% (3/17), 11.76% (2/17), and 11.76% (2/17) worked in Emergency rooms (ER), internal medicine and other departments in hospitals, respectively. Among the 57 of 98 SARS-HCP cases with their information of working departments available, ER (31.58%, 18/57), wards of internal medicine (26.31%, 15/57), and ICU (10.53%, 6/57) and other wards (31.58%, 18/57) were the four major working sites **([Table 1](#pone.0149988.t001){ref-type="table"}).** Our statistics for department will be heavily biased because of the missing department information in the HCP infections with MERS and SARS-CoV.

Among total 169 hospital-acquired MERS cases, patients accounted for 46.2%, family members or visitors 34.9%, and HCP (19.0%)**.** Among the 227 laboratory-confirmed SARS cases from hospital infections, HCP accounted the highest (43.2%), followed by patients (28.6%), family members or visitors (19.8%), foreign caregivers (4.4%), and others (4.0%). Nurses were the major populations in both groups **([Fig 4A and 4B](#pone.0149988.g004){ref-type="fig"}).**

![The occupational categories of hospital-associated MERS infections (n = 169) in Korea, 2015 and SARS infections (n = 227) in Taiwan, 2003.\
Notes: 4a: Occupational distribution in MERS-HCP. 4b: Occupational distribution in SARS-HCP.](pone.0149988.g004){#pone.0149988.g004}

Clinical comparison {#sec011}
-------------------

### Clinical spectrum {#sec012}

The percentages of asymptomatic cases \[36.72% (47/128) vs 17.39% (16/92), *p =* 0.001\] and mild cases \[43.75% (56/128) vs 18.48% (17/92), *p* \<0.001\] in HCP were much higher than those in non-HCP. However, the percentage of severe MERS cases in HCP was significantly lower than that in non-HCP \[12.5% (16/128) vs 27.17% (25/92), *p =* 0.006)\]. Similarly, CFR of MERS-HCP was statistically lower than that in MERS-non-HCP \[(7.0% (9/128) vs 36.96% (34/92), *p*\<0.001\] **[Table 2](#pone.0149988.t002){ref-type="table"}.** By contrast, severe SARS cases were more common in HCP than in non-HCP \[86.76% (86/98) vs 75.50% (188/249), *p =* 0.012\]. Nonetheless, CFR of SARS in HCP was significantly lower than that in non-HCP \[12.24% (12/98) vs.24.50% (61/249), *p =* 0.012, **[Table 2](#pone.0149988.t002){ref-type="table"}**\]. In general, MERS-HCP were predominantly associated with mild cases whereas SARS-HCP were more likely to develop severe cases. On the other hand, MERS-non-HCP cases had higher CFR than SARS-non-HCP cases \[36.96% (34/92) vs 24.50% (61/249), *p =* 0.023, **[Table 2](#pone.0149988.t002){ref-type="table"}.**

10.1371/journal.pone.0149988.t002

###### Clinical comparisons of the laboratory-confirmed human infections with MERS-CoV and SARS-CoV between healthcare personnel (HCP) and non-HCP.

![](pone.0149988.t002){#pone.0149988.t002g}

  Clinical Characteristics          MERS-CoV (+)      SARS-CoV (+)     Comparisons                                                          
  --------------------------------- ----------------- ---------------- ------------- ---------------- ------------------ ------- ---------- ----------
  **Clinical Severity**                                                                                                                     
      Asymptomatic                  36.72% (47/128)   17.39% (16/92)   \<0.0001      0.00% (0/98)     0.00% (0/249)      0.012   \<0.0001   \<0.0001
      Mild                          43.75% (56/128)   18.48% (17/92)   \<0.0001      0.00% (0/98)     0.00% (0/249)      0.012   \<0.0001   \<0.0001
      Severe                        12.50% (16/128)   27.17% (25/92)   \<0.0001      86.76% (86/98)   75.50% (188/249)   0.012   \<0.0001   \<0.0001
      Fatal                         7.03% (9/128)     36.96% (34/92)   \<0.0001      12.24% (12/98)   24.50% (61/249)    0.012   \<0.0001   \<0.0001
  **Clinical Symptoms**                                                                                                                     
      Fever (\>38°C)                58.54% (75/128)   97.83% (90/92)   \<0.001       95.92% (94/98)   83.94% (209/249)   0.003   \<0.001    \<0.001
      Cough                         63.41% (81/128)   83.70% (77/92)   \<0.001       33.67% (33/98)   38.55% (96/249)    0.397   \<0.001    \<0.001
      Chills or rigors              55% (70/128)      84.78% (78/92)   \<0.001       7.14% (7/98)     2.01% (5/249)      0.018   \<0.001    \<0.001
      Sore throat                   17.07% (22/128)   14.00% (13/92)   0.541         3.06% (3/98)     3.21% (8/249)      0.942   \<0.001    \<0.001
      Runny nose                    9.76% (12/128)    0.00% (0/92)     0.006         1.02% (1/98)     1.20% (3/249)      0.884   0.007      0.686
      Haemoptysis                   0.00% (0/128)     17.00% (16/92)   \<0.001       0.00% (0/98)     0.00% (0/249)      NA      NA         NA
      Shortness of breath           48.78% (62/128)   73.91% (68/92)   \<0.001       1.02% (1/98)     8.43% (21/249)     0.010   \<0.001    \<0.001
      Headache                      0.00% (0/128)     9.78% (9/92)     \<0.001       2.04% (2/98)     4.02% (10/249)     0.364   0.365      0.07
      Myalgia                       14.63% (19/128)   32.61% (30/92)   0.001         12.24% (12/98)   5.62% (14/249)     0.035   0.574      \<0.001
      Malaise                       0.00% (0/128)     38.00% (35/92)   \<0.001       1.02% (1/98)     1.20% (3/249)      0.884   0893       \<0.001
      Nausea                        0.00% (0/128)     21.00% (19/92)   \<0.001       1.02% (1/98)     0.00% (0/249)      0.628   0893       \<0.001
      Vomiting                      0.00% (0/128)     21.00% (19/92)   \<0.001       2.04% (2/98)     0.80% (2/249)      0.331   0.365      \<0.001
      Diarrhea                      2.44% (3/128)     26.00% (24/92)   \<0.001       13.27% (13/98)   12.05% (30/249)    0.757   0.004      0.002
      Rhinorrhea                    4.88% (6/128)     5.43% (5/92)     0.082         0.00% (0/98)     0.00% (0/249)      NA      0.079      0.002
  **Disease Progression (Days)**                                                                                                            
      Incubation period             7 (3\~11)         5 (2.0\~15)      0.150         6 (1\~15)        5 (4\~6)           0.250   0.890      0.640
      From onset to admission       5 (0\~11)         5 (1\~14)        0.480         2 (0\~14)        3 (0\~42)          0.261   0.010      0.470
      From onset to confirmation    6 (1\~14)         10 (1\~21)       0.044         2 (0\~20)        3 (0\~42)          0.416   0.250      0.770
      From onset to death           13 (4\~17)        12 (1\~52)       0.930         14.5 (0\~52)     12 (0\~83)         0.277   0.045      0.200
      From onset to be discharged   11 (5\~24)        12 (3\~30)       0.690         24 (0\~74)       19 (2\~92)         0.002   0.010      0.010

**Denotations:** *p*~*1*~: comparison of HCP and Non-HCP cases infected with MERS-CoV; *p*~*2*:~ comparison of HCP and Non-HCP cases infected with SARS-CoV; *p*~*3*~ comparison of HCP infected with MERS-CoV and SARS-CoV; *p*~*4*~ value represents comparison of Non-HCP infected with MERS-CoV and SARS-CoV. NA: No available data

\*SARS-CoV Data were obtained from Taiwan.

### Clinical manifestations {#sec013}

Detailed investigations on clinical manifestations of these two infections in HCP and non-HCP demonstrated that cough was the most frequent symptom in MERS-HCP \[63.41% (81/128)\], whereas fever was the most common symptom in MERS-non-HCP \[97.83% (90/92)\]. Additionally, both diarrhea and shortness of breath (SOB) were higher in the MERS-non-HCP compared to the MERS-HCP \[26.00% (24/92) vs 2.44% (3/128), *p\<*0.001; *73*.*91*% (68/92) vs 48.78% (62/128), *p\<*0.001, respectively\] (**[Table 2](#pone.0149988.t002){ref-type="table"}**).

### Time periods for clinical progress {#sec014}

Three time periods useful for public health surveillance were evaluated **([Table 2](#pone.0149988.t002){ref-type="table"}).** In MERS groups, the incubation period (the days from exposure to the clinical presentations) showed no differences between MERS-HCP and MERS-non-HCP \[7 (3\~11) vs 5 (2.0\~15), *p =* 0.150\] or between SARS-HCP and SARS-non-HCP cases \[6 (1\~15) vs 5 (4\~6), *p =* 0.250\]. The days from onset to being discharged and to death between the two groups also revealed similar results. By contrast, MERS-HCP cases had significantly shorter days from onset to laboratory-confirmation than MERS-non-HCP \[6 (1\~14) vs 10 (1\~21), *p =* 0.044\].

In SARS groups, among the three measures, only the days from onset to being discharged showed a difference, with significantly shorter days for SARS-HCP than SARS-non-HCP \[19 (2\~92) vs 24 (0--74), *p =* 0.002\]. **[Table 2](#pone.0149988.t002){ref-type="table"}**

Among the HCP with SARS and MERS infections, MERS-HCP had significantly longer days from onset to admission than SARS-HCP \[5 (0\~11) vs 3 (0\~14), *p =* 0.010\] but a shorter period from onset to being discharged \[11 (5\~24) vs 24 (0\~74), *p =* 0.010)\] and to death \[13 (4\~17) vs 14.5 (0\~52), *p =* 0.045\] and be hospitalized days \[9.5 (3\~22) vs 22 (0\~69), p = 0.040\] in MERS-HCP than those in SARS-HCP. **[Table 2](#pone.0149988.t002){ref-type="table"}**

To minimize the case fatality rate in MERS-HCP and SARS-HCP, we analyzed the epidemiology about the deaths related to HCP infections. 10 fatal MERS-HCP cases from Saudi Arabia, UAE and Jordan, as well as 13 fatal SARS-HCP cases in Taiwan were included **([Table 3](#pone.0149988.t003){ref-type="table"}).** The mean age of fatal MERS-HCP cases was 50 (26\~67), 70% of them were male, and 40% (4/10) had comorbidities. Similarly, the mean age of the fatal SARS-HCP cases was 49 (28\~68), 64.29% of whom were female. 69.23% (9/13) of SARS-HCP cases had accompanying co-morbidities. We found that fatality was most often found in age 50\~ groups with co-mortality in both the MERS-HCP and SARS-HCP groups respectively. Most of the fatal SARS-HCP were hired care workers (30.77% (; 4/13), or cleaners or nurses (15.38% (; 2/13). Importantly, the mean age in fatal HCP with the two infections was much older than in survivors of HCP with these infections.

10.1371/journal.pone.0149988.t003

###### Clinical and epidemiological characteristics of fatal infections with MERS-CoV vs SARS-CoV in healthcare personnel (HCP).

![](pone.0149988.t003){#pone.0149988.t003g}

  Groups     Epidemiological information   Clinical information   Data source                                                                                     
  ---------- ----------------------------- ---------------------- ------------- --------- ----------------------- ------------------ ----- ---------- ----------- ----------------------------------------------------------------------------------------
  HCP-MERS   Saudi Arabia                  Confirmed              41            F         HCP                     Unknown            No    Deceased   Unknown     <http://www.moh.gov.sa/en/CCC/pressreleases/pages/mediastatement-2013-09-05-001.aspx>
  HCP-MERS   Saudi Arabia                  Confirmed              56            Unknown   HCP                     Unknown            No    Deceased   Unknown     <http://www.moh.gov.sa/en/CoronaNew/P...09-07-001.aspx>
  HCP-MERS   Saudi Arabia                  Confirmed              40            F         HCP                     Unknown            Yes   Deceased   Unknown     <http://www.moh.gov.sa/en/CCC/PressRe...02-28-001.aspx>
  HCP-MERS   Saudi Arabia                  Confirmed              54            M         HCP                     Unknown            Yes   Deceased   1/14/2014   <http://www.peninsulatimes.org/2014/0...gladeshi-mers/>
  HCP-MERS   Saudi Arabia                  Confirmed              26            M         Nurse                   ER                 No    Deceased   4/5/2014    <http://www.aleqt.com/2014/03/28/article_836865.html>
  HCP-MERS   UAE                           Confirmed              45            M         HCP                     Unknown            No    Deceased   4/10/2014   <http://www.who.int/csr/don/2014_04_14_mers/en/>
  HCP-MERS   Jordan                        Confirmed              56            M         HCP                     Unknown            Yes   Deceased   5/6/2014    <http://www.assabeel.net/important/it...88%D9%86%D8%A7>
  HCP-MERS   Saudi Arabia                  Probable               67            M         Doctor (Cardiologist)   Unknown            Yes   Deceased   9/5/2013    x<http://www.alsharq.net.sa/2013/06/16/869245>
  HCP-MERS   Saudi Arabia                  Confirmed              60            M         Dermatologist           Unknown            No    Deceased   5/12/2014   <http://www.saudigazette.com.sa/index.cfm?method=home.regcon&contentid=20140514205096>
  HCP-MERS   Saudi Arabia                  Confirmed              54            M         Home care Doctor        Private hospital   No    Deceased   5/12/2014   <http://www.saudigazette.com.sa/index.cfm?method=home.regcon&contentid=20140514205096>
  HCP-SARS   Taiwan                        Confirmed              52            F         HCW                     Unknown            Yes   Deceased   4/19/2004   Provided by Taiwan University
  HCP-SARS   Taiwan                        Confirmed              42            M         Laundry staff           Laundry room       Yes   Deceased   4/29/2003   Provided by Taiwan University
  HCP-SARS   Taiwan                        Confirmed              37            F         Administration          Internal ward      No    Deceased   5/28/2003   Provided by Taiwan University
  HCP-SARS   Taiwan                        Confirmed              47            F         Nurse                   Unknown            No    Deceased   5/1/2003    Provided by Taiwan University
  HCP-SARS   Taiwan                        Confirmed              28            M         Doctor                  Internal ward      Yes   Deceased   5/15/2003   Provided by Taiwan University
  HCP-SARS   Taiwan                        Confirmed              41            F         Microbiologist          Testing Lab        Yes   Deceased   6/12/2003   Provided by Taiwan University
  HCP-SARS   Taiwan                        Confirmed              57            M         Care giver              Internal ward      Yes   Deceased   4/29/2003   Provided by Taiwan University
  HCP-SARS   Taiwan                        Confirmed              58            M         Care giver              Internal ward      No    Deceased   5/4/2003    Provided by Taiwan University
  HCP-SARS   Taiwan                        Confirmed              57            F         Cleaner                 Cleaning room      Yes   Deceased   5/3/2003    Provided by Taiwan University
  HCP-SARS   Taiwan                        Confirmed              49            F         Nurse                   Unknown            Yes   Deceased   5/18/2003   Provided by Taiwan University
  HCP-SARS   Taiwan                        Confirmed              59            M         Cleaner                 Cleaning room      Yes   Deceased   5/27/2003   Provided by Taiwan University
  HCP-SARS   Taiwan                        Confirmed              51            F         Care giver              Ward               No    Deceased   5/23/2003   Provided by Taiwan University
  HCP-SARS   Taiwan                        Confirmed              68            F         Care giver              Ward               Yes   Deceased   7/16/2003   Provided by Taiwan University

**Denotations:** ER = Emergency room; HCP = Healthcare Personnel

Discussion {#sec015}
==========

MERS-CoV and SARS-CoV infections are caused by the β group of the Coronaviruses (The genomic size of coronaviruses ranges from approximately 26 to 32 kilobases, the largest for an RNA virus), but the two Coronaviruses have different sources of infection and evolution, as shown by phylogenetic studies \[[@pone.0149988.ref002], [@pone.0149988.ref012]\]. One unique common epidemiological characteristic of these two diseases is that the spread of both MERS-CoV and SARS-CoV infection has been largely driven by hospital-associated human-to-human transmission where HCP are affected the most. In addition, these two emerging infections displayed four major differences. First, the geographical distributions for the two infections were different, in that MERS cases occurred mostly in the Middle East areas and South Korea, but a significantly higher number of SARS cases happened in Asia, predominantly in Chinese-concentrated countries and areas, including China. The differing patterns of cases between MERS and SARS may represent varying ecological situations, animal-human contact behavior, surveillance, control efforts, and cross-country spread, etc. \[[@pone.0149988.ref007]\]. A recent imported MERS case from Korea to Guangdong, China resulted in zero cases in China, further supporting the public health significance of surveillance and contact tracing for emerging infectious diseases. As the spread of MERS has continued, additional countries and areas are anticipated to have future outbreaks due to unexpected new imported cases \[[@pone.0149988.ref013]\]. Secondly, the two diseases vary in the transmissibility and effectiveness of containment. SARS-CoV cases spread rapidly through person-to-person transmission, aided by super spreaders, and finally reached 8096 total cases and affected 29 countries worldwide in an 8-month period \[[@pone.0149988.ref014]\]. However, the MERS-CoV cases spread at a slower speed, resulting in less of an emergency than SARS, with a total of at least 1382 cases (as of 11 August 2015), and attacked 26 countries worldwide in a period of over 39 months, without successful containment \[[@pone.0149988.ref015]\]. However, the South Korean outbreak in hospital involved MERS coronaviruses, with early super-spreading events (29 cases) generating a disproportionately large number of secondary infections, and the transmission potential diminishing greatly in subsequent generations \[[@pone.0149988.ref016]\]. Aron J. et al. reported 48 health care worker contacts with one death with MERS-CoV, and showed no evidence of MERS-CoV infection, which suggested the transmission was limited, without sustained transmission \[[@pone.0149988.ref012]\]. Thirdly, global MERS cases had a CFR of 35.6%, much higher than the 9.6% in global SARS cases \[[@pone.0149988.ref017]\]. This high CFR was probably because many mild and even asymptomatic infections have not been identified, due to insufficient public health resources in the Middle East \[[@pone.0149988.ref018]\]. The actual CRF for MERS is most likely lower than the currently documented rate. However, the CFR varied for different areas, countries and ages. The CFR was 21% among overall MERS cases sourced from health settings\[[@pone.0149988.ref007]\]. CFR among patients aged 60 years or older under treatment was estimated at 48.2%, while the CFR among other cases was estimated to lie below 15%.The risk of MERS death was significantly associated with older age as well as treatment for underlying diseases, etc. \[[@pone.0149988.ref017]\]. Fourthly, for the MERS cases, 72% (118/163) were found in Saudi Arabia, where the mean age showed its predominance in older males, in contrast to SARS casesin the Taiwan. A gender difference was found in the different age subgroups among two groups. The differences between MERS-HCP and SARS-HCP did not contribute to the age differences between the HCP populations in Saudi Arabia and Taiwan, because the HCP distribution was similar in the two countries. The reasons are not fully understood, but have been attributed to cultural practices in which older men may be more likely to come in contact with camels and other MERS-CoV-positive animals, and male HCP may be more common in the healthcare settings in the Middle East \[[@pone.0149988.ref019]\].

HCP are the population at highest risk of getting the infection and transmitting the two respiratory CoV due to occupational exposure, and thus are affected mostly in nosocomial outbreaks. The outbreak of SARS in 2003 tragically highlighted a high CFR in HCP \[[@pone.0149988.ref005]\]. HCP with exposure to MERS-CoV also were found as a personal and family health risks and social stigmatization. Further epidemiological analyses found that younger nurses were the most affected for both diseases compared to total cases. In contrast, MERS-HCP cases were different from SARS-HCP cases, as shown by: (1) a lower percentage of total MERS cases from this study (13.37% vs 21.07%) \[supported by the lower seroprevalence of HCP-MERS-CoV \[[@pone.0149988.ref012]\]\]; (2) younger age and more male nurses (probably due to either occupational exposure or a cultural relationship \[[@pone.0149988.ref020]\]; (3) HCP acquiring the MERS-CoV mostly in ICU (compared to ER for most of the SARS-CoV cases) consistent with other reports \[[@pone.0149988.ref021]\]. Park BJ, et al. also reported that HCP exposure occurred most frequently in the emergency department (69%) and among nurses (47%) \[[@pone.0149988.ref022]\]. In other words, HCP with high-risk occupational exposure and working in high-risk areas of medical institutions should be well-educated, alerted, and tested once they demonstrate respiratory-related symptoms/signs, as in Toronto's experience \[[@pone.0149988.ref023]\].

The clinical course of MERS generally follows a pattern typical of SARS infections. Our research estimated the incubation periods were 5\~7 days in MERS-HCP and SARS-HCP groups, as documented from other reports \[[@pone.0149988.ref024]\]. Differently, the days from onset to confirmation in MERS-HCP were much shorter than for the total MERS cases. This is attributed to the fact that most HCP hade close contact with the primary case and under medical observation. Importantly, the clinical period (from onset to outcome) was much shorter in MERS-HCP than in SARS-HCP. This shows that MERS infections were much more severe, due to higher respiratory tract viral loads, than SARS infections \[[@pone.0149988.ref025]\]. In addition, this difference was related not only to detection capability, and earliness of medical seeking behavior, but also to medical care handling.

Coronavirus infections range from asymptomatic infection to severe pneumonia and even death. However, there are several important differences between both infections \[[@pone.0149988.ref017]\]. Firstly, the incidence of asymptomatic and mild infection remains 0.1% for the general population, and there are higher rates for HCP with SARS-CoV (0.22%, n = 453) in Beijing, China \[[@pone.0149988.ref026]\], far lower than that of MERS infections overall and in HCP respectively. As most MERS-HCP infections were identified in secondary cases, mainly as mild disease or asymptomatic infection \[[@pone.0149988.ref008]\], those MERS-HCP remained a potential infection source of MERS-CoV. Thus, there is an urgent need for developing a rapid, sensitive, and specific diagnostic test to confirm MERS-CoV infection \[[@pone.0149988.ref027]\]. Secondly, 70% (7/10) of fatal MERS-HCP were identified in male workers, while 61.5% (8/13) of fatal SARS-HCP were in female workers. However, the deadly cases were most often found in those in their 50s age groups with underlying diseases in both the MERS-HCP and SARS-HCP groups respectively. This sex distribution was attributed to gender occupational exposure, sanitation behaviors and gender-specific comorbidities. As for similarities, CFR for both HCP infections were much lower than that of overall infections. This might mean that MERS-HCP and SARS-HCP were due to early confirmation, as well as due to the younger age with fewer accompanying comorbidities and professional guidance in HCP groups. Another common point was that the fatal MERS-HCP and SARS-HCP cases were both associated with older age with comorbidities (e.g., diabetes, hematological diseases, smoking, etc.), as recorded in other reports \[[@pone.0149988.ref028]\].

The experience from controlling SARS in Asia was that nosocomial outbreak was associated with a lack of awareness of and preparedness for emerging infections. So, to prevent disease transmission to HCP, early and rapid detection of patients suspected of being infected with MERS SARS diseases would be beneficial to reduce the HCP and patient infections \[[@pone.0149988.ref013]\]. The second group of risks were overcrowding, medical operations generating virus-containing aerosols, and poorly ventilated environments. Another risk was substandard infection control practices. Therefore, future effort should include more comprehensive ways to control MERS-HCP infections. Firstly, pubic heath effort needs to emphasize establishing systems for early recognition and reporting of HCP cases through a computer-based syndrome surveillance system \[[@pone.0149988.ref029]\]. These vigilant virologic and epidemiologic surveillance for MERS and SARS viruses should be conducted in HCP in nationwide in winter and spring of every year, which will be valuable to decrease the incidence, severity and transmission of two viruses in HCP working in health settings. Secondly, environmental control should be implemented through better engineering design, ventilation and disinfection in hospitals, regular monitoring and check-up and management policies \[[@pone.0149988.ref030]\]. Thirdly, rigorous training and practice of the standard operating infection-control procedures, including isolation of suspected or confirmed MERS-CoV cases, putting on and taking off personal protective equipment (PPE) and evaluations thereafter, are necessary.

Ethical Considerations {#sec016}
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The MERS data were obtained from publicly available data sources. Since SARS was a legally required notifiable disease in Taiwan in 2003, the data of SARS cases were centralized as a data bank for group data analysis only. All these data were provided and analyzed in an anonymous format, without access to personally identifying information.
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###### Summary of SARS-HCP cases with onset of illness from November 1 of 2002 to December 31, 2003.
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ARDS

:   Acute respiratory distress syndrome

CFR

:   Case-fatality rate

ELISA

:   Enzyme-linked immunosorbent assay

ER

:   Emergency room

HCP

:   Healthcare Personnel

HH

:   Households

ICU

:   Intensive care unit

IFA

:   Immunofluorescent antibody

ILI

:   Influenza-like illness

MERS

:   Middle East Respiratory Syndrome

MERS-CoV

:   Middle East Respiratory Syndrome Coronavirus

PPE

:   Personal protective equipment

rRT-PCR

:   Reverse transcription polymerase chain reaction

SARS

:   Severe Acute Respiratory Syndrome

SARS-CoV

:   Severe Acute Respiratory Syndrome Coronavirus

SOB

:   Shortness of breath
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